(Oct. 9, 2018) — The Food and Drug Administration (FDA) has cleared the MAGNETOM Sola, a 1.5 Tesla magnetic resonance imaging (MRI) scanner from Siemens Healthineers that brings groundbreaking BioMatrix technology to the 1.5T market. This technology addresses patient anatomical and physiological differences, as well as differences in how users set up and conduct MRI exams, to increase productivity and decrease rescans for improved efficiency and patient satisfaction. With the MAGNETOM Sola, Siemens Healthineers is expanding precision medicine and transforming the delivery of patient care.
Combined with Dot workflow engines and Tim 4G technology, the software accelerates scanning from positioning to post-processing with continual quality control of image data. The result is increased productivity and consistency across patients and exams.
“With the MAGNETOM Sola, we provide the 1.5T market with the latest MRI advancements designed to overcome the challenges of imaging diverse patient populations,” said Jane Kilkenney, Vice President of Magnetic Resonance, Siemens Healthineers North America. “By delivering unmatched levels of automation and personalization that address patient and user variability, we enable customers to achieve high-quality imaging – consistently and efficiently – across all patients and procedures.”
A cardiovascular edition of the MAGNETOM Sola – which includes high-performance hardware and software such as Compressed Sensing Cardiac Cine, MyoMaps, and the Cardiac Dot engine – is also available.
View original article on Siemens Healthineers website.
Contact for Journalists
Jeff Bell
Siemens Healthineers
Phone: (610) 448-6348; Email: jeffery.t.bell@siemens-healthineers.com
Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to achieve better outcomes at lower costs by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.
In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.8 billion and profit of €2.5 billion and has about 48,000 employees worldwide. Further information is available at www.siemens.com/healthineers.
Cassling strengthens community healthcare through customer-centric imaging and therapeutic technology, services and solutions. From critical access hospitals and diagnostic imaging centers to large health systems and IDNs, Cassling is committed to helping healthcare organizations improve access and outcomes, create efficiencies and lower costs.
Comments